{"source_content":"1本报告版权属于安信证券股份有限公司。各项声明请参见报告尾页。2020业绩快报：医美板块发力，构建泛时尚产业生态圈■归母净利高增，医美板块业务发力：2月26日朗姿股份发布业绩快报，FY2020收入28.73亿元/-4.46%，营业利润1.53亿元/-1.92%、利润总额1.32亿元/6.60%，公司归母净利1.37亿元/+134%。疫情背景下，女装业务收入13.28亿元/-13.40%，医美业务收入8.13亿元/+29.13%，童装业务收入7.32亿元/-7.97%。归母净利润的高增长主要由于FY2019计提L&P长期股权投资减值损失1.17亿元使得当年该项为低基数，同时本年医美板块高增带来贡献。■疫情影响减退，女装、童装业务有望恢复：2020年度，公司女装业务受疫情影响较大，经过在全渠道运营策略的加速推进和疫情后渠道布局的优化、产品品类的优化和增加、追单率的提升、店铺爆款打造等方面采取有力措施，实现女装业务营业收入13.28亿元（收入占比46.21%），童装业务收入7.32亿元（收入占比25.49%）。随着疫情影响逐渐消退，女装及童装恢复势头良好，未来有望逐步恢复至疫情前水平。■战略布局医美板块，构建泛时尚产业生态圈：朗姿先后战略投资韩国著名医疗美容服务集团DMG、收购控股“米兰柏羽”、“晶肤医美”、“高一生”三大国内优质医美品牌及其旗下18家（2020Q3）医疗美容机构，快速切入医疗美容行业。目前朗姿旗下机构遍布于成都、西安、深圳、重庆与长沙等地。公司战略性切入医美赛道，以收购+扩张形式快速扩张，采用连锁发展模式和区域化管理体系，1）降低前期投资，优化和充分利用同区域内店铺资源，对高端或大型成本较高设备可采用共享模式；2）共享医生资源，晶肤品牌下产品和服务的标准化程度较高，业务操作流程规范统一，医生可根据顾客求美需要提供标准化服务的同时，在不同的医美机构之间进行流动化作业；3）事业部中后台平台化的管理和服务职能，提高了管理效率，统一品牌推广和产品营销，机构间的协调性和协同性增强，增强了顾客粘性，同时有利于提升品牌的影响力。■医美机构市场增长迅速，龙头医疗美容服务机构竞争壁垒已经形成：2019年中国医疗外科诊疗市场占整个医疗美容服务市场的58.2%，达到人民币836亿元，复合年增长率为21.1%。中国私立医疗美容服务市场极度分散，CR5市场份额仅占总市场的7.2%（2017），正规机构占比仍然较低，监管趋严背景下大浪淘沙，市场整合有利于促进行业更加成熟及提高医疗美容服务的整体质量。优秀医疗美容服务机构竞争壁垒已经形成，已进入市场多年的医美机构拥有明显的先发优势。初期投入大，资本密集成为最大壁垒；行业监管标准趋严，合规成本逐渐Table_Title2021年02月28日朗姿股份（002612.SZ）Table_BaseInfo公司快报证券研究报告高端及奢侈品投资评级买入-A首次评级6个月目标价：元股价（2021-02-26）29.68元Table_MarketInfo交易数据总市值（百万元）13,131.78流通市值（百万元）7,757.14总股本（百万股）442.45流通股本（百万股）261.3612个月价格区间7.04/33.49元Table_Chart股价表现资料来源：Wind资讯升幅%1M3M12M相对收益44.53106.78252.91绝对收益41.67114.3286.68刘文正分析师SAC执业证书编号：S1450519010001liuwz@essence.com.cn021-35082109杜一帆分析师SAC执业证书编号：S1450518080002duyf1@essence.com.cn021-35082088王朔报告联系人wangshuo2@essence.com.cnTable_Report相关报告-16%30%76%122%168%214%260%2020-032020-072020-11朗姿股份中小1002本报告版权属于安信证券股份有限公司。各项声明请参见报告尾页。增加，进一步抬高新进入者门槛；医生团队品牌效应已经显现，优秀医美团队自带流量。朗姿旗下“米兰柏羽”及“高一生”均为老牌口碑医美医院，深获消费者认可；“晶肤”瞄准皮肤管理细分赛道，服务的标准化程度高，商业模式可迅速复制扩张。■投资建议：买入-A投资评级。我们预计公司2020年-2022年的收入分别为28.73亿元，34.18亿元，40.00亿元，对应增速分别为-4.5%、19.0%、17.0%，净利润分别为1.38亿元，2.20亿元，3.36亿元，对应增速分别为133.6%、59.8%、53.0%，成长性突出，首次给予买入-A的投资评级。■风险提示：1）女装及童装业务恢复不及预期；2）医美机构扩张不及预期；3）疫情反复影响等。(百万元)201820192020E2021E2022E主营收入2,661.53,007.32,873.33,418.14,000.5净利润210.558.8137.6219.9336.3每股收益(元)0.480.130.310.500.76每股净资产(元)6.286.737.026.896.34盈利和估值201820192020E2021E2022E市盈率(倍)62.4223.495.559.739.0市净率(倍)4.74.44.24.34.7净利润率7.9%2.0%4.8%6.4%8.4%净资产收益率7.6%2.0%4.4%7.2%12.0%股息收益率0.8%1.1%1.1%2.2%4.1%ROIC16.2%2.4%5.5%9.1%10.6%数据来源：Wind资讯，安信证券研究中心预测3公司快报/朗姿股份本报告版权属于安信证券股份有限公司。各项声明请参见报告尾页。财务报表预测和估值数据汇总利润表财务指标(百万元)201820192020E2021E2022E(百万元)201820192020E2021E2022E营业收入2,661.53,007.32,873.33,418.14,000.5成长性减:营业成本1,119.21,255.81,258.61,510.41,796.3营业收入增长率13.1%13.0%-4.5%19.0%17.0%营业税费20.320.321.024.728.4营业利润增长率7.0%-34.8%-2.6%67.7%43.7%销售费用956.51,129.01,018.11,240.91,360.2净利润增长率12.2%-72.1%134.1%59.8%53.0%管理费用299.5279.6336.3367.5423.4EBITDA增长率43.8%17.7%-45.0%59.1%24.1%研发费用82.7103.462.799.4113.8EBIT增长率48.2%24.6%-49.2%70.1%26.8%财务费用180.3105.7103.6179.9185.0NOPLAT增长率44.4%-80.0%154.4%70.1%26.8%资产减值损失76.7-127.15.7-14.9-45.4投资资本增长率37.4%10.1%1.6%9.2%-0.7%加:公允价值变动收益---107.629.439.3净资产增长率13.7%-14.0%2.4%-2.5%-8.5%投资和汇兑收益297.1156.8192.5215.5188.3营业利润239.5156.1152.1255.1366.5利润率加:营业外净收支-12.1-14.6-21.0-12.3-12.3毛利率57.9%58.2%56.2%55.8%55.1%利润总额227.5141.4131.1242.8354.1营业利润率9.0%5.2%5.3%7.5%9.2%减:所得税23.1100.732.860.788.5净利润率7.9%2.0%4.8%6.4%8.4%净利润210.558.8137.6219.9336.3EBITDA/营业收入17.6%18.3%10.6%14.1%15.0%EBIT/营业收入15.2%16.7%8.9%12.7%13.8%资产负债表运营效率201820192020E2021E2022E固定资产周转天数5449503930货币资金258.093.9229.9273.4320.0流动营业资本周转天数118124113121121交易性金融资产-265.088.3117.8157.0流动资产周转天数393334284320297应收帐款422.2460.4448.7601.3621.7应收帐款周转天数5653575555应收票据0.80.40.90.51.2存货周转天数118117120123124预付帐款24.647.95.063.623.3总资产周转天数962746649658636存货952.8997.3910.91,416.01,344.0投资资本周转天数373402444394350其他流动资产2,005.150.8928.3994.7658.0可供出售金融资产274.8-123.0132.685.2投资回报率持有至到期投资-----ROE7.6%2.0%4.4%7.2%12.0%长期股权投资654.81,187.71,187.71,187.71,187.7ROA2.8%0.8%1.9%2.5%3.9%投资性房地产477.8395.0395.0395.0395.0ROIC16.2%2.4%5.5%9.1%10.6%固定资产395.0419.4384.3349.2314.1费用率在建工程98.7135.7135.7135.7135.7销售费用率35.9%37.5%35.4%36.3%34.0%无形资产382.2400.4387.7374.9362.2管理费用率11.3%9.3%11.7%10.8%10.6%其他非流动资产1,335.4845.11,721.01,267.21,209.6研发费用率3.1%3.4%2.2%2.9%2.8%资产总额7,282.05,180.25,180.77,309.66,814.6财务费用率6.8%3.5%3.6%5.3%4.6%短期债务1,777.1375.31,298.91,662.32,101.4四费/营业收入57.1%53.8%52.9%55.2%52.1%应付帐款323.4378.2363.5505.9526.1偿债能力应付票据-----资产负债率41.2%30.4%45.6%49.6%50.6%其他流动负债273.4326.6442.8528.5354.2负债权益比70.0%43.8%84.0%98.6%102.3%长期借款95.47.0678.4451.3-流动比率1.541.771.241.291.05其他非流动负债528.5525.9386.7480.4464.4速动比率1.140.850.810.760.60负债总额2,997.71,613.13,170.43,628.43,446.1利息保障倍数2.244.762.472.422.98少数股东权益1,504.7707.8670.5633.4564.2分红指标股本400.0435.1442.4442.4442.4DPS(元)0.230.320.330.651.20留存收益2,377.22,548.32,663.12,605.42,361.9分红比率47.5%238.4%106.0%130.6%158.3%股东权益4,284.33,685.83,776.13,681.23,368.5股息收益率0.8%1.1%1.1%2.2%4.1%现金流量表业绩和估值指标201820192020E2021E2022E201820192020E2021E2022E净利润204.340.7137.6219.9336.3EPS(元)0.480.130.310.500.76加:折旧和摊销86.983.447.847.847.8BVPS(元)6.286.737.026.896.34资产减值准备76.7127.0---PE(X)62.4223.495.559.739.0公允价值变动损失---107.629.439.3PB(X)4.74.44.24.34.7财务费用177.4100.4103.6179.9185.0P/FCF-1,099.0-7.58.6109.739.1投资损失-301.1-160.0-194.9-218.6-191.2P/S4.94.44.63.83.3少数股东损益-6.1-18.1-39.3-37.7-70.7EV/EBITDA8.48.644.829.023.7营运资金的变动830.31,267.9-981.376.237.1CAGR(%)-3.8%86.8%-20.1%-3.8%86.8%经营活动产生现金流量54.4596.7-1,034.0296.8383.7PEG-16.62.6-4.7-15.90.4投资活动产生现金流量140.1786.6-172.7-26.1453.8ROIC/WACC1.60.20.50.91.1融资活动产生现金流量-142.1-1,546.31,342.7-227.2-790.9REP0.85.76.93.93.4资料来源：Wind资讯，安信证券研究中心预测4公司快报/朗姿股份本报告版权属于安信证券股份有限公司。各项声明请参见报告尾页。公司评级体系收益评级：买入—未来6-12个月的投资收益率领先沪深300指数15%以上；增持—未来6-12个月的投资收益率领先沪深300指数5%至15%；中性—未来6-12个月的投资收益率与沪深300指数的变动幅度相差-5%至5%；减持—未来6-12个月的投资收益率落后沪深300指数5%至15%；卖出—未来6-12个月的投资收益率落后沪深300指数15%以上；风险评级：A—正常风险，未来6-12个月投资收益率的波动小于等于沪深300指数波动；B—较高风险，未来6-12个月投资收益率的波动大于沪深300指数波动；Table_AuthorStatement分析师声明刘文正、杜一帆声明，本人具有中国证券业协会授予的证券投资咨询执业资格，勤勉尽责、诚实守信。本人对本报告的内容和观点负责，保证信息来源合法合规、研究方法专业审慎、研究观点独立公正、分析结论具有合理依据，特此声明。本公司具备证券投资咨询业务资格的说明安信证券股份有限公司（以下简称“本公司”）经中国证券监督管理委员会核准，取得证券投资咨询业务许可。本公司及其投资咨询人员可以为证券投资人或客户提供证券投资分析、预测或者建议等直接或间接的有偿咨询服务。发布证券研究报告，是证券投资咨询业务的一种基本形式，本公司可以对证券及证券相关产品的价值、市场走势或者相关影响因素进行分析，形成证券估值、投资评级等投资分析意见，制作证券研究报告，并向本公司的客户发布。免责声明本报告仅供安信证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因为任何机构或个人接收到本报告而视其为本公司的当然客户。本报告基于已公开的资料或信息撰写，但本公司不保证该等信息及资料的完整性、准确性。本报告所载的信息、资料、建议及推测仅反映本公司于本报告发布当日的判断，本报告中的证券或投资标的价格、价值及投资带来的收入可能会波动。在不同时期，本公司可能撰写并发布与本报告所载资料、建议及推测不一致的报告。本公司不保证本报告所含信息及资料保持在最新状态，本公司将随时补充、更新和修订有关信息及资料，但不保证及时公开发布。同时，本公司有权对本报告所含信息在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。任何有关本报告的摘要或节选都不代表本报告正式完整的观点，一切须以本公司向客户发布的本报告完整版本为准，如有需要，客户可以向本公司投资顾问进一步咨询。在法律许可的情况下，本公司及所属关联机构可能会持有报告中提到的公司所发行的证券或期权并进行证券或期权交易，也可能为这些公司提供或者争取提供投资银行、财务顾问或者金融产品等相关服务，提请客户充分注意。客户不应将本报告为作出其投资决策的惟一参考因素，亦不应认为本报告可以取代客户自身的投资判断与决策。在任何情况下，本报告中的信息或所表述的意见均不构成对任何人的投资建议，无论是否已经明示或暗示，本报告不能作为道义的、责任的和法律的依据或者凭证。在任何情况下，本公司亦不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。本报告版权仅为本公司所有，未经事先书面许可，任何机构和个人不得以任何形式翻版、复制、发表、转发或引用本报告的任何部分。如征得本公司同意进行引用、刊发的，需在允许的范围内使用，并注明出处为“安信证券股份有限公司研究中心”，且不得对本报告进行任何有悖原意的引用、删节和修改。本报告的估值结果和分析结论是基于所预定的假设，并采用适当的估值方法和模型得出的，由于假设、估值方法和模型均存在一定的局限性，估值结果和分析结论也存在局限性，请谨慎使用。安信证券股份有限公司对本声明条款具有惟一修改权和最终解释权。5公司快报/朗姿股份本报告版权属于安信证券股份有限公司。各项声明请参见报告尾页。Table_Address安信证券研究中心深圳市地址：深圳市福田区深南大道2008号中国凤凰大厦1栋7层邮编：518026上海市地址：上海市虹口区东大名路638号国投大厦3层邮编：200080北京市地址：北京市西城区阜成门北大街2号楼国投金融大厦15层邮编：100034Table_Sales销售联系人上海联系人潘艳上海区域销售负责人18930060852panyan@essence.com.cn侯海霞上海区域销售总监13391113930houhx@essence.com.cn朱贤上海区域销售总监13901836709zhuxian@essence.com.cn李栋上海区域高级销售副总监13917882257lidong1@essence.com.cn刘恭懿上海区域销售副总监13916816630liugy@essence.com.cn苏梦上海区域销售经理13162829753sumeng@essence.com.cn秦紫涵上海区域销售经理15801869965qinzh1@essence.com.cn陈盈怡上海区域销售经理13817674050chenyy6@essence.com.cn徐逸岑上海区域销售经理18019221980xuyc@essence.com.cn北京联系人张莹北京区域销售负责人13901255777zhangying1@essence.com.cn张杨北京区域销售副总监15801879050zhangyang4@essence.com.cn温鹏北京区域销售副总监13811978042wenpeng@essence.com.cn刘晓萱北京区域销售副总监18511841987liuxx1@essence.com.cn王帅北京区域销售经理13581778515wangshuai1@essence.com.cn游倬源北京区域销售经理010-83321501youzy1@essence.com.cn侯宇彤北京区域销售经理18210869281houyt1@essence.com.cn深圳联系人张秀红深圳基金组销售负责人0755-82798036zhangxh1@essence.com.cn胡珍深圳基金组高级销售副总监13631620111huzhen@essence.com.cn范洪群深圳基金组销售副总监18926033448fanhq@essence.com.cn聂欣深圳基金组销售经理13540211209niexin1@essence.com.cn杨萍深圳基金组销售经理0755-82544825yangping1@essence.com.cn黄秋琪深圳基金组销售经理13699750501huangqq@essence.com.cn喻聪深圳基金组销售经理18503038620yucong@essence.com.cn马田田深圳基金组销售经理18318054097matt@essence.com.cn","data":[{"id":"1","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"FY2020收入28.73亿元/-4.46%","content_offset":["90","112"],"indicators":[{"indicator_name":"营业收入","indicator_value":["28.73亿元","98","105"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"FY2020收入28.73亿元/-4.46%","content_offset":["90","112"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-4.46%","106","112"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"营业利润1.53亿元/-1.92%","content_offset":["113","130"],"indicators":[{"indicator_name":"营业利润","indicator_value":["1.53亿元","117","123"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"营业利润1.53亿元/-1.92%","content_offset":["113","130"],"indicators":[{"indicator_name":"营业利润同比","indicator_value":["-1.92%","124","130"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"利润总额1.32亿元/6.60%","content_offset":["131","147"],"indicators":[{"indicator_name":"利润总额","indicator_value":["1.32亿元","135","141"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"利润总额1.32亿元/6.60%","content_offset":["131","147"],"indicators":[{"indicator_name":"利润总额同比","indicator_value":["6.60%","142","147"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","40","42"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"公司归母净利1.37亿元/+134%","content_offset":["148","166"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1.37亿元","154","160"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","65","67"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"公司归母净利1.37亿元/+134%","content_offset":["148","166"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["+134%","161","166"],"indicator_element":{"公司":["朗姿股份","79","83"],"行业":["医美","65","67"],"时间":["FY2020","90","96"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"医美业务收入8.13亿元/+29.13%","content_offset":["195","215"],"indicators":[{"indicator_name":"营业收入","indicator_value":["8.13亿元","201","207"],"indicator_element":{"公司":["朗姿股份","1155","1159"],"行业":["医美","195","197"],"时间":["FY2020","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"医美业务收入8.13亿元/+29.13%","content_offset":["195","215"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+29.13%","208","215"],"indicator_element":{"公司":["朗姿股份","1155","1159"],"行业":["医美","195","197"],"时间":["FY2020","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"我们预计公司2020年-2022年的收入分别为28.73亿元，34.18亿元，40.00亿元，","content_offset":["1803","1850"],"indicators":[{"indicator_name":"营业收入","indicator_value":["28.73亿元","1826","1833"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1707","1709"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入","indicator_value":["34.18亿元","1834","1841"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1707","1709"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入","indicator_value":["40.00亿元","1842","1849"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1707","1709"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"12","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"对应增速分别为-4.5%、19.0%、17.0%","content_offset":["1850","1874"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-4.5%","1857","1862"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入同比","indicator_value":["19.0%","1863","1868"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入同比","indicator_value":["17.0%","1869","1874"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"13","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"净利润分别为1.38亿元，2.20亿元，3.36亿元","content_offset":["1875","1901"],"indicators":[{"indicator_name":"净利润","indicator_value":["1.38亿元","1881","1887"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["2.20亿元","1888","1894"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["3.36亿元","1895","1901"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"14","source_document":"朗姿股份（002612）2020业绩快报：医美板块发力，构建泛时尚产业生态圈.pdf","content":"对应增速分别为133.6%、59.8%、53.0%","content_offset":["1902","1927"],"indicators":[{"indicator_name":"净利润同比","indicator_value":["133.6%","1909","1915"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润同比","indicator_value":["59.8%","1916","1921"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润同比","indicator_value":["53.0%","1922","1927"],"indicator_element":{"时间":["2020年-2022年","1809","1820"],"公司":["朗姿股份","2348","2352"],"行业":["医美","1972","1974"]},"indicator_supplement":{"属性":"预计"}}]}]}